Value-Based Pharmaceutical Contracts: Value for Whom?

Value Health

The Queen's Health Systems, Honolulu, HI, USA.

Published: February 2020

Value-based pharmaceutical contracts (VBPCs) are performance-based reimbursement agreements between healthcare payers and pharmaceutical manufacturers in which the price, amount, or nature of reimbursement is tied to value-based outcomes. VBPCs are often complex, and the nature of who benefits and in what ways can be unclear. We discuss how VBPCs compare with value-based payer-provider arrangements in terms of performance-based reimbursements and alignment of incentives. In addition, we examine how VBPCs can affect costs, clinical outcomes, and access to medications. Because these contracts are unlikely to reduce costs in isolation, we recommend taking a patient-centered approach when developing VBPCs and tying VBPCs to more overarching payer drug cost reduction strategies.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jval.2019.10.009DOI Listing

Publication Analysis

Top Keywords

value-based pharmaceutical
8
pharmaceutical contracts
8
vbpcs
6
value-based
4
contracts whom?
4
whom? value-based
4
contracts vbpcs
4
vbpcs performance-based
4
performance-based reimbursement
4
reimbursement agreements
4

Similar Publications

Importance: Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common cause of chronic liver disease and is projected to become the leading indication for liver transplant (LT) in the US. Understanding its clinical burden can help to identify opportunities for prevention and treatment.

Objective: To project the burden of MASLD in US adults from 2020 to 2050.

View Article and Find Full Text PDF

Value-Based Pricing for Drugs With Uncertain Clinical Benefits.

Health Econ

January 2025

Department of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.

Policymakers can use cost-effectiveness analysis to set value-based prices (VBP) for new pharmaceuticals. However, the uncertainty of investigational drug benefits complicates this pricing strategy. Such complexity stems from decision-makers' risk aversion and the potential change in the estimated value with emerging evidence.

View Article and Find Full Text PDF

Introduction/objectives: Patients living with chronic diseases require more medical attention, including more visits to primary care. However, primary care providers are overburdened, and this specialty is attracting fewer new providers than before. Clinical pharmacists can augment these efforts by improving disease state control.

View Article and Find Full Text PDF

Current approaches to the pricing and funding of new pharmaceuticals often focus on a one-time decision about a product for each clinical indication. This can result in multiple options being available to health systems without a clear signal about how to prioritise between them. This runs the risk that, as available treatments, evidence, and drug prices evolve, clinical and patient choices may not be aligned with the objective of allocating resources to promote population health.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!